KalVista Announces Ekterly as First-Line Treatment for Hereditary Angioedema
KalVista announced that the newly published International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema recommends Ekterly as a first-line therapy for the acute treatment of hereditary angioedema attacks in adolescents aged 12 years and older. Based on robust, high-quality evidence, including clinical trial data demonstrating consistent efficacy, rapid symptom relief and a favorable safety profile, the guideline committee issued a strong recommendation for the first-line use of sebetralstat in adolescents 12 and older with HAE. The recommendation comes just months after the launch of Ekterly in the U.S. and Germany and follows seven global regulatory approvals received in 2025. Ekterly is the first and only oral on-demand treatment for people 12 and older with HAE.
